Aerie Pharmaceuticals, Inc. – NASDAQ:AERI

Add to watchlist

Market closed

Open in 2 days

-100.00%

month

-100.00%

quarter

-100.00%

year

Market Cap	N/A
Enterprise value	1.01B

P/E	-19.94
EV/Sales	4.73
EV/EBITDA	-329.26
Price/Sales	3.40
Price/Book	-4.44
PEG ratio	-0.33
EPS	-0.75

Revenue	213.94M
EBITDA	-3.07M
Income	-36.55M
Revenue Q/Q	23.25%
Revenue Y/Y	105.41%

Profit margin	-17.09%
Oper. margin	-12.49%
Gross margin	89.01%
EBIT margin	-12.49%
EBITDA margin	-1.44%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI): Profit margin
Dec 2021	114.66M	45.53M	39.71%
Mar 2022	29.83M	-35.89M	-120.3%
Jun 2022	33.31M	-19.37M	-58.15%
Sep 2022	36.12M	-26.82M	-74.25%

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI): Earnings per share (EPS)
2022-02-24	-0.67	1.09
2022-05-05	-0.65	-0.66
2022-08-04	-0.56	-0.32
2022-11-03	-0.42	-0.27

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI): Debt to assets
Dec 2021	431391000	448.72M	104.02%
Mar 2022	395546000	521.25M	131.78%
Jun 2022	385340000	526.47M	136.63%
Sep 2022	375590000	539.57M	143.66%

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI): Cash Flow
Dec 2021	-30.11M	2.06M	3.38M
Mar 2022	61.91M	-42.3M	-357K
Jun 2022	-13.23M	-3.93M	166K
Sep 2022	-11.40M	25.86M	188K

Aerie Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Aerie Pharmaceuticals
Employees

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI): Employee count
Aug 2023	376
Sep 2023	376
Oct 2023	376
Nov 2023	376
Dec 2023	376
Jan 2024	376
Feb 2024	376
Mar 2024	376
Apr 2024	376
May 2024	376
Jun 2024	376
Jul 2024	376

Aerie Pharmaceuticals
Insider Trading

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI): Insider trades (number of shares)
Period	Buy	Sel
Feb 2020	0	1000000
May 2020	0	5000
Nov 2020	0	30000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	15 Feb 2021	KOPCZYNSKI CASEY C. officer: Chief Sc..	Stock Option (right to buy)	60,651	$0.2	$11,888
Option	15 Feb 2021	KOPCZYNSKI CASEY C. officer: Chief Sc..	Common Stock	60,651	$0.2	$11,888
Sale	11 Nov 2020	KOPCZYNSKI CASEY C. officer: Chief Sc..	Common Stock	22,695	$13.01	$295,217
Sale	10 Nov 2020	KOPCZYNSKI CASEY C. officer: Chief Sc..	Common Stock	7,305	$13	$94,965
Option	18 May 2020	GOLDBERG MURRAY A director director	Stock Option (right to buy)	28,000	$3.15	$88,200
Option	18 May 2020	GOLDBERG MURRAY A director director	Common Stock	28,000	$3.15	$88,200
Sale	8 May 2020	CAGLE GERALD D. director	Common Stock	5,000	$15.27	$76,350
Sale	27 Feb 2020	FORESITE CAPITAL MANAGEMENT II, LLC 10 percent owner 10 percent owner	Common Stock	1,000,000	$17.07	$17,070,000
Option	3 Dec 2019	KOPCZYNSKI CASEY C. officer: Chief Sc..	Stock Option (right to buy)	117,000	$0.41	$47,385
Option	3 Dec 2019	KOPCZYNSKI CASEY C. officer: Chief Sc..	Common Stock	117,000	$0.41	$47,385

AERI insider trading transactions

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Ophthalmic compositions Filling date: 30 Aug 2017 Issue date: 19 Jul 2022	30 Aug 2017	19 Jul 2022
Application	Application MONO-(ACID) SALTS OF 6-AMINOISOQUINOLINES AND USES THEREOF Filling date: 14 Oct 2021 Issue date: 12 May 2022	14 Oct 2021	12 May 2022
Application	Application MEDICAL IMPLANT Filling date: 3 Nov 2021 Issue date: 5 May 2022	3 Nov 2021	5 May 2022
Grant	Grant Utility: Aryl cyclopropyl-amino-isoquinolinyl amide compounds Filling date: 22 Jul 2020 Issue date: 26 Apr 2022	22 Jul 2020	26 Apr 2022
Application	Application COMBINATION THERAPY Filling date: 7 Dec 2021 Issue date: 24 Mar 2022	7 Dec 2021	24 Mar 2022
Grant	Grant Utility: Combination therapy Filling date: 23 Apr 2021 Issue date: 14 Dec 2021	23 Apr 2021	14 Dec 2021
Grant	Grant Utility: Compositions for treating glaucoma or reducing intraocular pressure Filling date: 23 Apr 2021 Issue date: 30 Nov 2021	23 Apr 2021	30 Nov 2021
Application	Application DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE Filling date: 28 Apr 2021 Issue date: 25 Nov 2021	28 Apr 2021	25 Nov 2021
Application	Application ISOQUINOLINE-STEROID CONJUGATES AND USES THEREOF Filling date: 4 Jun 2021 Issue date: 30 Sep 2021	4 Jun 2021	30 Sep 2021
Grant	Grant Utility: Compounds, compositions and methods for treatment of myopia Filling date: 31 Jan 2020 Issue date: 14 Sep 2021	31 Jan 2020	14 Sep 2021

Aerie Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q2 2022 7 Aug 2022	Q2 2022 Earnings Call Transcript
Q1 2022 7 May 2022	Q1 2022 Earnings Call Transcript
Q4 2021 24 Feb 2022	Q4 2021 Earnings Call Transcript
Q3 2021 7 Nov 2021	Q3 2021 Earnings Call Transcript

AERI earnings call transcripts

Aerie Pharmaceuticals
Executives

Insider	Age	Compensation
Mr. Thomas A. Mitro (1958) Pres & Chief Operating Officer	67	$747,680
Dr. Casey C. Kopczynski (1961) Co-Founder & Chief Scientific Officer	64	$665,580
Mr. John W. LaRocca Esq. (1965) Gen. Counsel & Sec.	60	$658,860
Dr. David A. Hollander M.B.A., M.D. (1974) Chief R&D Officer	51	$648,770
Dr. Benjamin F. McGraw III, J.D., Pharm.D. (1949) Executive Chairman	76	$92,500

Aerie Pharmaceuticals
Latest News

Tuesday, 22 November 2022
01:01	Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical Business	businesswire.com
Thursday, 3 November 2022
19:36	Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates	Zacks Investment Research
Friday, 21 October 2022
10:33	Add These 4 Top-Ranked Liquid Stocks For Healthy Gains	Zacks Investment Research
09:47	5 Small Hidden Gems Flying High Despite Market's Bloodbath	Zacks Investment Research
Thursday, 20 October 2022
12:02	5 Stocks to Bet on in an Innovation-Driven Drug Industry	Zacks Investment Research
Monday, 17 October 2022
11:17	Are Medical Stocks Lagging Aerie Pharmaceuticals (AERI) This Year?	Zacks Investment Research
Thursday, 29 September 2022
11:17	Is Aerie Pharmaceuticals (AERI) Stock Outpacing Its Medical Peers This Year?	Zacks Investment Research
Monday, 12 September 2022
11:17	Is Aerie Pharmaceuticals (AERI) Outperforming Other Medical Stocks This Year?	Zacks Investment Research
Friday, 26 August 2022
11:18	Has Aerie Pharmaceuticals (AERI) Outpaced Other Medical Stocks This Year?	Zacks Investment Research
09:03	Why Aerie Pharmaceuticals Was Soaring So High This Week	The Motley Fool
Wednesday, 24 August 2022
16:02	Don't Look for Alcon's Acquisition to Boost Share Price in Short Term	GuruFocus
Tuesday, 23 August 2022
12:47	Aerie (AERI) to be Acquired by Alcon for $770M, Shares Up	Zacks Investment Research
03:45	Alcon to Acquire Aerie Pharmaceuticals for $15.25 a Share	Barrons
Wednesday, 17 August 2022
11:17	After Golden Cross, Aerie Pharmaceuticals (AERI)'s Technical Outlook is Bright	Zacks Investment Research
Sunday, 7 August 2022
09:49	Aerie Pharmaceuticals, Inc.'s (AERI) CEO Raj Kannan on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
Friday, 5 August 2022
13:33	Aerie (AERI) Q2 Loss Narrower Than Expected, Sales Beat	Zacks Investment Research
Thursday, 4 August 2022
18:48	Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates	Zacks Investment Research
Thursday, 28 July 2022
18:10	Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET	Business Wire
Wednesday, 25 May 2022
16:03	Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease	Zacks Investment Research
Saturday, 7 May 2022
03:48	Aerie Pharmaceuticals' (AERI) CEO Raj Kannan on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha
Friday, 6 May 2022
17:18	Aerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/Y	Zacks Investment Research
Monday, 11 April 2022
16:33	Aerie (AERI) Expands Market Presence Despite Stiff Competition	Zacks Investment Research
Sunday, 27 February 2022
15:16	Aerie Pharmaceuticals (AERI) Stock: Why It Substantially Increased	Pulse2
Thursday, 24 February 2022
21:48	Aerie Pharmaceuticals, Inc. (AERI) CEO Raj Kannan on Q4 2021 Results - Earnings Call Transcript	Seeking Alpha
Wednesday, 23 February 2022
13:06	Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More	Zacks Investment Research
Thursday, 17 February 2022
16:45	Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022 at 5:00 p.m. ET	Business Wire
Tuesday, 9 November 2021
16:30	Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences	Business Wire
Sunday, 7 November 2021
05:30	Aerie Pharmaceuticals' (AERI) Management on Q3 2021 Results - Earnings Call Transcript	Seeking Alpha
Friday, 5 November 2021
12:13	Aerie's (AERI) Q3 Earnings Miss Estimates, Revenues Rise Y/Y	Zacks Investment Research
Thursday, 4 November 2021
18:19	Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates	Zacks Investment Research

Frequently Asked Questions (FAQ)

When is Aerie Pharmaceuticals's next earnings date?

Unfortunately, Aerie Pharmaceuticals's (AERI) next earnings date is currently unknown.
Does Aerie Pharmaceuticals pay dividends?

No, Aerie Pharmaceuticals does not pay dividends.
What is Aerie Pharmaceuticals's stock symbol?

Aerie Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "AERI".
What is Aerie Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
How do i buy shares of Aerie Pharmaceuticals?

Shares of Aerie Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Aerie Pharmaceuticals's key executives?
Aerie Pharmaceuticals's management team includes the following people:
- Mr. Thomas A. Mitro Pres & Chief Operating Officer(age: 67, pay: $747,680)
- Dr. Casey C. Kopczynski Co-Founder & Chief Scientific Officer(age: 64, pay: $665,580)
- Mr. John W. LaRocca Esq. Gen. Counsel & Sec.(age: 60, pay: $658,860)
- Dr. David A. Hollander M.B.A., M.D. Chief R&D Officer(age: 51, pay: $648,770)
- Dr. Benjamin F. McGraw III, J.D., Pharm.D. Executive Chairman(age: 76, pay: $92,500)
Is Aerie Pharmaceuticals founder-led company?

Yes, Aerie Pharmaceuticals is a company led by its founder Dr. Casey C. Kopczynski.
How many employees does Aerie Pharmaceuticals have?

As Jul 2024, Aerie Pharmaceuticals employs 376 workers.
When Aerie Pharmaceuticals went public?

Aerie Pharmaceuticals, Inc. is publicly traded company for more then 11 years since IPO on 25 Oct 2013.
What is Aerie Pharmaceuticals's official website?

The official website for Aerie Pharmaceuticals is aeriepharma.com.
Where are Aerie Pharmaceuticals's headquarters?

Aerie Pharmaceuticals is headquartered at 4301 Emperor Blvd Ste 400, Durham, NORTH CAROLINA.
How can i contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals's mailing address is 4301 Emperor Blvd Ste 400, Durham, NORTH CAROLINA and company can be reached via phone at +1 919 237 5300.

Aerie Pharmaceuticals, Inc.

aeriepharma.com

Exchange:

NASDAQ

Full time employees:

376

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

+1 919 237 5300

4301 Emperor Blvd Ste 400
Durham, NORTH CAROLINA 27703

CIK: 0001337553
ISIN: US00771V1089
CUSIP: 00771V108